One of the greatest benefits of antibody drugs is the safety as this same molecule constitutes our natural defence system against antigens. However, this benefit turns into a barrier to efficient bioanalysis; methodology is needed to selectively detect administered antibody without interference from host-derived antibodies. Although LC-MS/MS is expected to be the alternative to the conventional ELISA technique for its robustness and ease of method development, strong ionization suppression exerted by high-abundance peptides derived from the constant (Fc) region limits the sensitivity of low-abundance peptides in the variable (Fab) region.
Nano-surface and molecular orientation limited proteolysis (nSMOL™) is Shimadzu’s proprietary, innovative technology that enables selective proteolysis of the Fab region of antibodies. Peptide sample prepared by the nSMOL kit has substantially lower complexity near-zero interference from host antibodies, thus enabling LC-MS/MS sensitivity to reach down to the level required for pre-clinical and clinical studies. This application news reports the fully-validated LC-MS/MS method developed for Trastuzumab determination in plasma.
To download your copy of this application note complete the form opposite.
Eclipse Business Media Ltd, Regd in England, No. 06513189, Woodview, Bull Lane Industrial Estate, Sudbury, CO10 0FD, United Kingdom, T +44 (0)161 818 7434, info@sepscience.com
Eclipse Business Media Ltd needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy or contact privacy@labxmediagroup.com
Copyright © 2023. All rights reserved